RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer today provides an update on the Company’s s Clinical Development and Strategic plans.
20190211-HBP-Press-Release-Clinical-Development-and-Strategic-Update-1.pdf